Company Description
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications.
The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model.
Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026.
Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
| Country | Israel |
| Founded | 2000 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Allen Baharaff |
Contact Details
Address: 16 Abba Hillel Road Ramat Gan, 5250608 Israel | |
| Phone | 972 3 693 8448 |
| Website | eocn.com |
Stock Details
| Ticker Symbol | EOCN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1595353 |
| ISIN Number | IL0011313900 |
| Employer ID | 98-1147233 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Allen Baharaff | Chief Executive Officer |
| Doron Cohen | Chief Financial Officer |
| Guy Nehemya | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2026 | 6-K | Report of foreign issuer |
| Sep 8, 2026 | 6-K | Report of foreign issuer |
| Sep 3, 2026 | EFFECT | Notice of Effectiveness |
| Sep 3, 2026 | 6-K | Report of foreign issuer |
| Sep 2, 2026 | POS AM | Post-Effective amendments for registration statement |
| Sep 2, 2026 | 6-K | Report of foreign issuer |
| Sep 2, 2026 | 6-K | Report of foreign issuer |
| Aug 19, 2026 | 6-K/A | Filing |
| Aug 19, 2026 | 6-K | Report of foreign issuer |
| Aug 17, 2026 | 6-K | Report of foreign issuer |